For decades, the medical community has faced a frustrating limitation in the fight against chronic traumatic encephalopathy. Because the disease, typically caused by repeated head impacts in sports or military service, can only be definitively diagnosed through a brain autopsy after death, doctors have been unable to help patients while they are still alive. This gap in diagnostics has stalled the development of preventative strategies and effective treatments for those suffering from memory loss, depression, and volatile mood swings.
Researchers at Boston University believe they may finally be closing that gap. In a recent study conducted alongside Banner Health, scientists analyzed blood samples from football players who had donated their brains upon death. By looking for specific proteins that act as markers for tau tangles—the toxic clumps that destroy neurons—they discovered that individuals with advanced CTE had significantly higher concentrations of certain proteins than those in early stages or healthy controls. Crucially, the team found they could potentially distinguish CTE from Alzheimer’s disease by comparing different biomarkers, providing a clearer picture of what is actually happening inside the patient’s brain.
Despite the excitement, outside experts caution that these findings are still in the discovery phase. Critics point out that the study relied on a very small sample size and lacked enough representation of people in the earliest stages of the disease to establish a reliable diagnostic threshold. Many neurologists argue that a simple blood test likely won’t be a silver bullet on its own but will instead become part of a larger toolkit involving brain imaging and clinical evaluations to ensure accuracy across diverse populations.
Even with these caveats, the scientific community sees this as a pivotal moment of optimism. Similar conclusions reached independently by researchers at Washington University in St. Louis suggest that these protein markers are legitimate targets for further study. For families like those of Richard McElroy, whose personality shifted violently due to late-stage CTE, such progress represents more than just data; it is the possibility that future athletes will receive answers and care long before their symptoms become devastating.




